The FDA unveiled a pilot program designed to speed early clinical development by pairing sponsors with research sites prequalified for key steps in the IND process. Under the program, sponsors can file trial plans for an expedited IND workflow on a rolling basis once matched with a qualifying research institution. The goal is to reduce time between IND preparation and first-in-human study initiation by coordinating parallel activities such as Institutional Review Board assessment and site activation. The FDA said the selected qualified research institutions will bring specialized expertise that enables FDA to review and accept IND components during the pre-IND phase rather than waiting for all components. Applications will be accepted until October 30, with eight to ten projects expected to be selected. For the industry, the pilot signals continued regulatory emphasis on earlier execution and fewer administrative bottlenecks in Phase I readiness.